Molecular and Immunologic Analysis of the Pathobiology of Human Anthrax Infections

Oklahoma Medical Research Foundation, Oklahoma City OK

Investigators

Linked publications & trials

Abstract

The present application is the second competing renewal of a CCHI grant first awarded in 2003 to study the human immune response to Bacillus anthracis and the toxin vaccine that is currently administered to the thousands of deployed US military. The goals of the original application were: (a) To study the human immune response to a challenging vaccine, (b) To understand the mechanism for the high lethality of the inhalation form of the disease, (c) To understand the cellular basis of the host response to the pathogen. Our published findings show, in contrast to prevailing views, that the high rate of mortality in inhalation anthrax is due to bacterial sepsis and not the anthrax toxins. In the most recent funding cycle, we made the seminal discovery that immune complexes between peptidoglycan (PGN) and pre-existing anti-PGN antibodies present in all humans may be the source of the massive inflammation accompanying infection by B. anthracis. Lastly, we discovered that fully 30% of vaccinees are almost certainly unprotected despite having been immunized more than 6 times in an onerous vaccine schedule. In this renewal application, we will follow up on these exciting discoveries to determine: (a) How do anthrax spores move from the alveoli to the mediastinal lymph nodes. (b) How PGN triggers an antimicrobial response by human immune cells and how anthrax toxins affect the response. (c) How PGN-anti-PGN immune complexes influence the outcome of the disease. (d) Why the vaccine is imperfect in stimulating the maturation of germinal center B cells, and whether elevated histones caused by toxin-impaired efferocytosis contributes to inflammation. Our work is supported by 3 scientific cores: An animal core that applies a non-human primate model established in the previous funding cycle; a flow cytometry core that has state-of-the-art capacity; and a human antibody core that will make recombinant human monoclonal antibodies using technology that was invented at our institute. The studies in this renewal application-are focused and thematically organized around the key roles of PGN, the anthrax toxins and the anthrax toxin vaccine in the human immune responses. They have great potential to identify novel means of interrupting the pathology caused by this model Gram-positive pathogen.